All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 4 read as filed from the record and 5 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2024; the latest 2025-10-27.
From the record
Basel Medical Group Ltd's filings since 2024 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2025-10-27) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
SI estimate 5.2/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Basel Medical Group Ltd's track record is put at 5.2 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 8 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
How has it treated the people who own it?
SI estimate 1.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Basel Medical Group Ltd's shareholder treatment is put at 1.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 17% of 9 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -196%: lost 196¢ per shareholder dollar. Leverage 71%: owes 71¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-06-30, Basel Medical Group Ltd lost about 196 cents for every dollar of shareholders' money. Leverage: it owed about 71 cents per dollar of assets, and net share issuance: its share count grew 15.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 28% of 9 in its family; net margin -94%.
From the record
Basel Medical Group Ltd's standing among 9 graded names in its industry family: revenue of SGD 11 million in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of -94% ranks in the bottom 6%; revenue growth of 12.6% a year over the last 1 filed years ranks in the top 50% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 6.7/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Basel Medical Group Ltd's leadership is put at 6.7 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-04 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 6 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 39% of 9 in its family for room to expand.
From the record
Basel Medical Group Ltd's room to grow, from the newest filed statements (fiscal 2025): cash of SGD 3 million against no long-term debt tagged leaves 16.3% of its assets as net cash, top 39% of its family; cash from operations less capital spending is -40.6% of revenue (bottom 17%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
SI estimate 5.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Basel Medical Group Ltd's growth drivers is put at 5.0 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 8 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
Did its newest year beat what its own record pointed to?
SI estimate 5.8/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Basel Medical Group Ltd's expectations vs reality is put at 5.8 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 6 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made